UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations

• Päätekijät: Sara Malaca (Tekijä), Massimo Gottardi (Tekijä), Federica Pigliasco (Tekijä), Sebastiano Barco (Tekijä), Alessia Cafaro (Tekijä), Elisabetta Amadori (Tekijä), Antonella Riva (Tekijä), Martina Marcenaro (Tekijä), Pasquale Striano (Tekijä), Giuliana Cangemi (Tekijä), Roberta Pacifici (Tekijä), Simona Pichini (Tekijä), Francesco Paolo Busardò (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2021-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. Recently, a purified form of CBD (Epidiolex^®) has been approved by the European Medicines Agency (EMA) for the treatment of two highly-refractory childhood-onset epileps...